You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma

  • Authors: Susan Schneider, PhD, RN, AOCN; Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP; Hussein Tawbi, MD, PhD; Michele Fierstein
  • CE Released: 5/19/2023
  • Valid for credit through: 5/19/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Nurses - 1.25 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for oncology nurses, oncology nurse practitioners (NPs), and other members of the melanoma care team.

The goal of this activity is for learners to be better able to mitigate potential adverse events (AEs) associated with lymphocyte-activation gene 3 (LAG3) inhibitors as well as leverage the patient voice in the care of patients potentially eligible for or already receiving LAG3 inhibitors for metastatic melanoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Safety data associated with LAG-3 inhibitors in metastatic melanoma
    • Strategies used to facilitate shared decision-making (SDM) practices in the care of patients with metastatic melanoma potentially eligible for or already receiving LAG-3 inhibitors
  • Have greater competence related to
    • Mitigating potential adverse events experienced by patients receiving LAG-3 inhibitors for metastatic melanoma
  • Demonstrate greater confidence in their ability to
    • Serve as a trusted liaison between the patient and other members of the melanoma treatment team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Chair

  • Susan Schneider, PhD, RN, AOCN

    Associate Professor Emerita
    Duke University
    Durham, North Carolina
    ONS Past President

    Disclosures

    Susan Schneider, PhD, RN, AOCN, has no relevant financial relationships.

Faculty

  • Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP

    Advanced Practice Registered Nurse
    Department of Melanoma Medical Oncology
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP, has no relevant financial relationships.

  • Hussein Tawbi, MD, PhD

    Professor
    Deputy Chair, Department of Melanoma Medical Oncology
    Co-Director, MD Anderson Brain Metastasis Clinic
    Melanoma Medical Oncology, Investigational Cancer Therapeutics
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Disclosures

    Hussein Tawbi, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Boxer Capital; Bristol Myers Squibb Company; Eisai Inc.; Genentech; Iovance; Jazz Pharmaceuticals, Inc.; Karyopharm Therapeutics; Medicenna; Merck; Novartis
    Research funding from: Bristol Myers Squibb Company; Dragonfly Therapeutics; Eisai Inc.; EMD Serono; Genentech; GlaxoSmithKline; Merck; Novartis; RAPT Therapeutics

  • Michele Fierstein

    Melanoma patient

    Disclosures

    Michele Fierstein, has no relevant financial relationships.

Editor

  • Deborah Middleton, MS

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Deborah Middleton, MS, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

Sunrise and Skin Cancer: A Look Into LAG-3 Inhibitors for the Treatment of Melanoma

Authors: Susan Schneider, PhD, RN, AOCN; Michelle L. Rohlfs, DNP, APRN, FNP-BC, AOCNP; Hussein Tawbi, MD, PhD; Michele FiersteinFaculty and Disclosures

CE Released: 5/19/2023

Valid for credit through: 5/19/2024, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to mitigate potential AEs associated with LAG3 inhibitors as well as leverage the patient voice in the care of patients potentially eligible for or already receiving LAG3 inhibitors for metastatic melanoma.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print